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Amphipterygium adstringens is a plant widely used in Mexican traditional medicine for its known anti-inflammatory and antiulcer
properties. In this work, we evaluated the in vitro antimicrobial and antiproliferative activities of the methanolic extract of A.
adstringens against oral pathogens such as Streptococcusmutans, Porphyromonas gingivalis,Aggregatibacter actinomycetemcomitans,
Candida albicans, and Candida dubliniensis, using microdilution (MIC) and agar diffusion methods (MBC), and the antiprolifer-
ative activity evaluating total growth inhibition (TGI) by staining the protein content with sulforhodamine B (SRB), using nine
human cancer cell lines. Crude extract (CE) of A. adstringens showed some degree of activity against one or more of the strains
with a MIC from 0.125mg/mL to 63mg/mL and MBC from 1.6 to 6.3mg/mL and cytotoxic activity, particularly against NCI-
ADR/RES, an ovarian cell line expressing multiple resistance drugs phenotype.The CE is a complex mixture of possible multitarget
metabolites that could be responsible for both antimicrobial and antiproliferative activities, and further investigation is required to
elucidate the identity of active compounds. Nevertheless the CE itself is useful in the development of new antimicrobial treatment
based on natural products to prevent oral diseases and as alternative natural source for cancer treatment and prevention.
1. Introduction
Natural molecules and products reemerge as promising
sources of complexmultitargetmixtures that are used as alter-
native therapeutic agents for various conditions, including
infections and chronic diseases [1, 2], such as oral diseases
[3–5] or digestive cancers [6].
Amphipterygium adstringens Schiede ex Schlecht (Julian-
aceae) is an endemic species in Mexico commonly known
as “cuachalalate.” A. adstringens is a dioecious tree of
approximately 5–10 meters in height and 40 cm in diameter,
with the twisted trunk, gray bark with large scales, and
rounded lenticels exposed and oblong leaves from 6 to 15 cm
(Figure 1), clustered at the tips of branches in numbers from
3 to 5 [7]. Its location is in the Mexican Pacific coastline from
Nayarit to Oaxaca, and other states of Mexico such as Puebla
and Morelos [8].
The bark has traditionally been used by healers to treat
gastritis, gastric ulcers [9], gastrointestinal cancer [10, 11],
colic, fever [12, 13], and also tooth pain [14]. Moreover,
anti-inflammatory [15], hypocholesterolemic [16], antifungal
[17], and antiprotozoal [18] activities have been reported as
properties for this plant. Recent studies have shown that
the active component responsible for the plant properties
is the anacardic acid [19] which exerts antioxidant, anti-
inflammatory [20], antitumoral [21], antiulcer and antimicro-
bial activities [9, 19].
A wide range of uses and diversity of biological activities
reported reminds us of a complex mixture of multitarget
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Figure 1: Whole plant and bark of Amphipterygium adstringens
growing in Michoacan, Mexico.
compounds, which is a common characteristic in several
medicinal plants and similar to others [22].
Microbial communities in themouth have been shown to
cause infectious diseases such as dental caries [23], candidi-
asis [24], gingivitis and periodontitis [25], and other chronic
or systemic diseases [26–28].
Streptococcusmutans is themain pathogenic agent related
to the initiation of dental caries. Its virulence relies on
its ability to form biofilms on teeth surface, to degrade
carbohydrates (particularly refined sugars from food) with
the formation of large amounts of organic acids that deminer-
alize tooth enamel, and to adapt and tolerate environmental
stresses, particularly low pH (aciduricity) [29].
Porphyromonas gingivalis and Aggregatibacter actino-
mycetemcomitans are bacteria often isolated from the subgin-
gival biofilm [30, 31] and associated with periodontitis and
gingivitis. Dental biofilm stimulates the release of proteolytic
enzymes, which cause disruption of the epithelial junction,
gingival and alveolar bone loss, increasing tooth mobility,
and, ultimately, tooth loss [32]. Dental biofilm induce a
peripheral neutrophil response [33] and it has been associated
with systemic conditions such as infective endocarditis [34],
cardiovascular disease [35], preterm and low birth weight
[36], and pancreatic cancer [37]. Additionally, the constantly
observed correlation between oral microbiome (especially
biofilm builders) [28] with chronic inflammatory disease and
cancer triggers the need for further research that contributes
with novel sources of bioactive compounds.
Oropharyngeal candidiasis, caused by Candida, is a local
infection commonly seen in infants, older adults who wear
dentures, patients treated with antibiotics, chemotherapy,
or radiation therapy on head and neck, and those with
cellular immune deficiency states, such as HIV infection
[38]. Moreover, Candida species are the fourth leading cause
of healthcare-associated infections, accounting for approxi-
mately 11% of all infections; Candida spp. are also responsible
for nearly 12% of all central line-associated bloodstream
infections, preceded only by Staphylococcus aureus and Ente-
rococcus species [39]. Candida albicans is often guilty in
oral candidiasis and has been implicated in persistent apical
periodontitis [40]. On the other side, Candida dubliniensis
was involved with denture stomatitis and oropharyngeal
candidiasis in immunocompromised subject [41, 42] and
has an invasive history in survival of head or neck cancers
patients [43]. Treatments for these infections have grown to
be a great challenge, because of a rise in the frequency of
infections and an increasing resistance to standard antifungal
therapy.
The increasing cancer incidence is closely related to the
raise in life expectancy and longevity that consequently
results in a longer exposure to carcinogenic agents such
as pollution, UV radiation, and microorganisms [44]. The
reduction of pathogens associated with systemic and oral
infections, using natural products to inhibit the ability to
form biofilms, could be an effective approach to prevent and
control oral diseases.
Moreover, there has been a decline in research, develop-
ment, and approvals of new antimicrobial agents. For exam-
ple, from 1983 to 1987 compared to from 1998 to 2002, there
was a 56% decrease in new antibacterial agents approved by
the FDA (Food and Drugs Administration). Among other
reasons, one main cause is the high cost with a low rate of
return compared to drugs used to treat chronic conditions,
limitations on the use of newly approved antibacterial agents,
and trial design and regulatory issues [45]. This engages the
scientific community to continue obtaining research-based
information towards the application and use of traditional
medicine that medical health care systems can rely on.
With this approach, we studied the antimicrobial activity
of CE of A. adstringens against microorganisms associated
with oral infections, and the possible antiproliferative effect
against a well-defined panel of human cancer cells lines.
This is, undoubtedly, a significant contribution in the field
of alternative medicine towards the elaboration of novel
antimicrobial agents to prevent and treat oral infections and
to reduce the potential risk of systemic chronic diseases and
cancer.
2. Materials and Methods
2.1. Plant Material. Amphipterygium adstringens bark was
obtained by Dr. Julia Verde from the Department of Chem-
istry, Faculty of Biological Sciences, Autonomous University
of Nuevo Leon (UANL). The taxonomic identification was
made by Dr. Mauricio Gonzalez, following the last revision
of the genus Amphipterygium (Julianaceae) [46]. A voucher
specimen was deposited as IB1 in the Institute of Biotechnol-
ogy, Faculty of Biological Sciences, UANL.
2.2. Preparation of Plant Extracts. The bark of A. adstringens
was air-dried at 45∘C and ground in a Wiley type mill to
a fine powder. About 390 g of powder was macerated with
500mL methanol by shaking at 100 rpm for 72 hours. The
extract was filtered with filter paper (Whatman Grade 1)
to remove debris and filter-sterilized with 0.20 𝜇m syringe
filter (Corning, NY). Extract was concentrated using a rotary
evaporator (Yamato RE801), under reduced pressure at 30∘C,
providing 52.7 g of crude extract.The crude extract was stored
at 4∘C until its use.
2.3. Determination of Antimicrobial Activity. The antimi-
crobial effect of the crude extract of A. adstringens was
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determined in a preliminary study using theKirby-Bauer disk
diffusionmethod [47] against several human pathogens (data
not shown). This scrutiny preceded the experimental design
to determine MIC and MBC/MFC of A. adstringens crude
extract against oral pathogens.
2.4. Microbial Growth Conditions. Strains were cultured fol-
lowing their specific requirements. S. mutans (ATCC 700610)
was cultured on BHI and 5%CO
2
. P. gingivalis (ATCC 33277)
and A. actinomycetemcomitans (ATCC 43718) was cultured
on TSB (Tryptic Soy Broth) and carried out in anaerobic
conditions. Escherichia coli (ATCC 43895) and Escherichia
coli (ATCC 0157-H7) were cultured on TSB in aerobic
atmosphere and were used as biological control to validate
microbicidal activity assay due to their multidrug resistance.
Candida albicans (CBS-562) and Candida dubliniensis (CBS-
7987) were cultured on Sabouraud dextrose agar in aerobic
conditions [48]. All strains were incubated at 35∘C for 48
hours. Chlorhexidine gluconate 0.12% (Sigma-Aldrich, St.
Louis, MO, USA) was used as positive control for bactericidal
activity due to its antibacterial spectrum against Gram-
positive and Gram-negative bacteria and actual application
on oral hygiene; Fluconazole (Pfizer), an oral azole, was
selected as positive control against Candida because it is
frequently used in patients who suffer oropharyngeal and
esophageal candidiasis.
2.5. Minimum Inhibitory Concentration (MIC). The mini-
mum inhibitory concentrations (MIC) were determined by
microdilution broth method according to the Clinical and
Laboratory Standards Institute [49], using 96-well plates.The
microbial inoculum was prepared and adjusted to 5 × 105
colony forming units (CFU)/mL. The CE was dissolved in
1% DMSO followed by dilution in tryptic soy broth, brain
heart infusion, or Sabouraud (depending on the strain), and,
then, serial twofold to threefold dilutions were made in a
concentration ranged from 78 to 0.01mg/mL, in sterile water.
96-well plates were incubated at 35∘C/24 hours aerobically
and anaerobically. MIC was determined as the lowest con-
centration of CE that inhibited microorganism growth. The
experiment was performed by duplicate in three independent
tests.
2.6. Minimum Bactericidal Concentration (MBC) and Min-
imum Fungicidal Concentration (MFC). The MBC or MFC
was determined removing the samples from the wells of the
microplate with no visible bacterial growth and subcultured
in agar (TBS, BHI, or Sabouraud), depending on the strain.
The lowest concentration of the subculture with no growth
was considered the minimum bactericidal concentration
(MBC) or the minimum fungicidal concentration (MFC).
2.7. Statistical Analysis. Results were expressed as mean ±
SD for analysis performed in triplicate. Statistical analysis of
the data was performed by Analysis of Variance (ANOVA)
followed by Duncan test using SPSS 17.0 software. Probability
values of 𝑃 ≤ 0.05 were considered to be significant.
2.8. Human Cell Lines Panel. Human tumor cell lines
U251 (CNS), UACC-62 (skin), and OVCAR (ovary); NCI-
ADR/RES (ovary multidrug resistant phenotype); 786-O
(kidney); NCI-H460 (non-small-cell lung); PC-3 (prostate);
HT-29 (colon); and K562 (bone marrow) were kindly pro-
vided by M. A. Frederick (National Cancer Institute, USA).
Stock culture was grown in 25 cm3 flasks cell cultures (Nunc)
with 5mL of RPMI-1640 (Gibco-BRL, Gran Island, NY, USA)
supplemented with 5% fetal bovine serum (FBS, Gibco-
BRL, Gran Island, NY, USA) plus penicillin/streptomycin
(1000 𝜇g/mL : 1000 IU/mL) and incubated at 37∘C in humid
atmosphere with 5% CO
2
. The cell line has less than 20
passages as laboratory good practices.
2.9. Antiproliferative Activity. In vitro antiproliferative activ-
ity was performed using preincubated (24 hours at 37∘C) cell
lines into 96-well plates (Nunc), which were exposed at 0.25,
2.5, 25, and 250 𝜇g/mL of A. adstringens CE for 48 hours.
Cells were fixed with 50% trichloroacetic acid (30min at 4∘C)
and cell proliferation was determined by spectrophotometric
quantification (540 nm) of cellular protein content using
sulforhodamine B assay. Using the concentration-response
curve for each cell line, total growth inhibition (TGI) was
defined as the concentration value that produces total growth
inhibition and was determined by nonlinear regression anal-
ysis using the software Origin 7.5 (OringinLab Corporation,
NorthamptonMA, USA).This value corresponded to the test
extract concentration necessary to inhibit proliferation of the
cells. Doxorubicin was used as positive control. The assay
was performed by triplicate per concentration of CE in three
independent tests.
3. Results
3.1. Antimicrobial Activity. Methanolic extract of A. adstrin-
gens used in this work showed antimicrobial activity against
all microbial strains tested with concentrations between
0.125 and 63mg/mL (Table 1). The most sensitive strain
was S. mutans with a MIC value of 0.125mg/mL and
MBC at 0.31mg/mL. Candida strains showed a MIC and
MFC of 0.4mg/mL and 1.6mg/mL, respectively. P. gingivalis
and Escherichia coli 43895 showed MIC/MBC values of
37mg/mL. Similar results are exhibited byA. actinomycetem-
comitans and Escherichia coli O157:H7 being inhibited at
63mg/mL. Pure chlorhexidine (positive control) showed
a MIC of 0.04mg/mL and a MBC of 2.4mg/mL, and
0.06mg/mL and 1.2mg/mL for Fluconazole.
3.2. Antiproliferative Activity. In this model, in vitro cytotox-
icity determination of the CE of A. adstringens demonstrated
total inhibition of tumor cell growth at concentrations rang-
ing from 7.30 to 27.50𝜇g/mL (Table 2) and showing the most
potent activity against ovary adenocarcinoma (4𝜇g/mL).
4. Discussion
There exists an increasing prevalence of infectionsworldwide,
due to, among other reasons, the growing resistance of
4 Evidence-Based Complementary and Alternative Medicine
Table 1: Antimicrobial activity of the crude extract of A. adstringens.
Pathogens Reference MIC∗(mg/mL) MBC∗∗/MFC∗∗∗(mg/mL)
Streptococcus mutans ATCC 700610 0.125 0.31a
Porphyromonas gingivalis ATCC 33277 37 37c
Aggregatibacter actinomycetemcomitans ATCC 43718 63 63c
Candida albicans CBS-562 0.4 1.6b∗∗∗
Candida dubliniensis CBS-7987 0.4 1.6b∗∗∗
Escherichia coli ATCC 43895 37 37c
Escherichia coli H7 ATCC 0157:H7 63 63c
Chlorhexidine SIGMA 0.04 2.4
Fluconazole SIGMA 0.06 1.2
The results represent the means ± SD from three independent experiments. Different letter represents statistically significant differences among pathogens
groups as determined by one-way ANOVA and Duncan test. Chlorhexidine and Fluconazole are controls.
∗MIC: minimum inhibitory concentration.
∗∗MBC: minimum bactericidal concentration.
∗∗∗MFC: minimum fungicidal concentration.
Table 2: Cell lines used in the evaluation of antiproliferative activity.
Cell line Organ/disease Origin tissue Total growth inhibition (𝜇g/mL)
CE DOX
U251 CNS; glioma Ectoderm 26.10 <0.025
UACC-62 Skin; melanoma Ectoderm 7.30 0.028
NCI-ADR/RES∗ Ovary; adenocarcinoma Ectoderm 26.40 >25.00
786-O Kidney; adenocarcinoma Mesoderm 28.00 0.038
NCI-H460 Lung; non-small-cell lung carcinoma Mesoderm 27.50 <0.025
PC-3 Prostate; adenocarcinoma Mesoderm 24.80 0.025
OVCAR-3 Ovary; adenocarcinoma Mesoderm 4.40 0.230
HT-29 Colon; adenocarcinoma Endoderm 7.90 0.026
K562 Bone marrow; chronic myeloid leukemia Mesenchyme >250 >25.00
Results are the mean ± SD of 3 replicates per treatment in three independent tests after 48 hours of treatment.
CE: crude extract of Amphipterygium adstringens.
DOX: doxorubicin (positive control).
∗Multidrug resistant cell line.
pathogens to antibiotics and antifungals as well as alterations
in the autoimmune system. Diseases as caries, periodontitis
and gingivitis, oropharyngeal candidiasis, and cancer have
had profound effects on human health. Microbial species
in oral cavity are commensals under normal physiological
conditions. The host immune response, supplemented by
excellent oral hygiene, is sufficient tomaintain healthy tissues.
However, failures in immune defense or plaque control result
in development of gingival inflammation [25–27].
In this investigation, we tested the crude extract of A.
adstringens, against oral pathogens and human cancer cell
lines and, as expected, we unambiguously demonstrated that
the methanolic extract exerts significant antimicrobial and
antiproliferative activities. Additionally our results provide
novel evidence that A. adstringens also exerts growth control
against Candida, and these results represent the first report
for this plant.
In regard of activity shown against S. mutans, our results
showed that inhibitory concentrations of A. adstringens
CE reached 0.125mg/mL (MIC) and 0.31mg/mL (MBC),
while chlorhexidine had MIC and MBC values of 0.4 and
2.4mg/mL, respectively. On the other hand, biocidal activity
against periodontopathogens showed that the crude extract
of A. adstringens had a MIC and MBC of 37mg/mL for P.
gingivalis and 63mg/mL forA. actinomycetemcomitans.These
results are consistent with previous work demonstrating
higher sensitivity of S. mutans than periodontopathogens to
medicinal plant components [19, 50, 51].
Chlorhexidine is the most common mouthwash product
used for caries and periodontal diseases and kills bacteria
by causing a precipitation or coagulation of the cytoplasmic
content. It is an effective antiplaque agent developed to date,
but it has been proven that prolonged use causes several
undesirable side effects; besides many clinical trials have
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shown that taste of chlorhexidine is not well accepted by
children [52]. Our results, along with previous reports of A.
adstringens, enhance proposals to include natural remedies as
components of mouthwash, toothpaste, and delivery systems
[53] to control dental plaque.
As for activity of A. adstringens CE against yeasts, our
findings indicated a strong antifungal activity showing MIC
andMBC values of 0.4mg/mL andMFC of 1.6mg/mL.Those
are the lowest among all MIC values shown in our data,
suggesting that A. adstringens components exert fungicidal
activity against candidiasis causal agents. By far, this repre-
sents our most original and promising evidence, considering
the continuous quest for new and improved products, with
emphasis placed on natural/nature identical compoundswith
the fewest side effects. Fluconazole is commonly used as
therapy for candidiasis in HIV and cancer patients, but the
rise in prevalence of fungal infections and drug resistance has
exacerbated the need of novel antifungal compounds. Our
results provide evidence of potential antifungal application of
A. adstringens offering an alternative therapy to fluconazole.
As mentioned before, oral microbiota diversity is closely
related to health conditions and systemic diseases such as
cardiovascular and inflammatory diseases and cancer. This
is why we designed experiments to holistically test both
biological activity against oral pathogens and antiproliferative
activity on human cancer cell lines.
The model used in this work to evaluate the antipro-
liferative activity was the assay with Sulforhodamine B (an
anionic dye) that allowed the evaluation of antitumor activity
through exposure of selected human tumor cell lines during
exponential growth phase, at different concentrations of the
A. adstringens extract determining total growth inhibition
(TGI) [54].
Antiproliferative activity of the CE showed lowest TGI
results on ovarian cancer OVCAR-3 adenocarcinoma with a
TGI= 4.4 𝜇g/mL, followed bymelanomaUACC-62 and colon
adenocarcinoma II HT-29 with TGI = 7.3 and 7.9 𝜇g/mL,
respectively. These are significant activities at low concen-
trations considering that CE is a mixture of nonpurified
compounds, such as those found in actual traditional use
of A. adstringens. Consistent with our results, other authors
reported A. adstringens activity with TGI = 20.4𝜇g/mL to
48.2 𝜇g/mL and 27.4𝜇g/mL to 38.3 𝜇g/mL in the cell lines
U251 and PC-3, respectively [10]. Similarly, low TGI values
for CE were proved in every tumor cell line included in the
selected panel.
Interestingly, NCI/ADR-RES ovarian tumor cell line,
expressing high levels of MDR1 and P-glycoprotein, which
are related to multidrug resistance [55, 56], showed best TGI
values (26.40 𝜇g/mL), whereas doxorubicin showed almost
no effect at concentrations of 25𝜇g/mL.
This data confirms that complexmixtures of plants, essen-
tial oils, and natural alternative therapeutics that have been
widely used in traditional medicine represent an effective,
safe, and evidence based treatment for acute and chronic
infections as well as chronic health conditions. Preparations
and formulations of this CE can be improved and applied for
daily use in dental products to prevent caries and periodontal
diseases and concomitantly weaken the risk of cancer.
5. Conclusions
The findings of the present study demonstrated a broad
potential using the heterogeneous mixture of CE of A.
adstringens, where the synergy of all components could be
acting against all the strains tested, especially against S.
mutans and Candida spp. A. adstringens has shown selective
antiproliferative activity against multidrug resistant cell line
NCI/ADR-RES. These effective antimicrobial and antipro-
liferative activities make A. adstringens a good candidate
for further development of antimicrobial products for oral
infectious therapy and cancer prevention and treatment.
However, further research should be made to test whether
secondarymetabolites fromA. adstringensmaintain reported
bioactivity when separated or act as a synergistic complex
mixture of phytochemicals.
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